MRGPRX4

Incyte Completes Acquisition of Escient Pharmaceuticals

Retrieved on: 
목요일, 5월 30, 2024
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Escient, Patient, Inflammation, Covington & Burling, Goldman Sachs, Atopic dermatitis, MRGPRX2, Cholestatic pruritus, CSU, Acquisition, LLP, MRGPRX4, Therapy, Centerview Partners, B cell, Pharmaceutical industry

Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders.
  • "We are excited to continue the work started by the Escient team and accelerate the clinical development of these promising therapies."
  • “Over the past six years, Escient has pioneered the characterization of MRGPR biology and advanced two novel candidates, EP262 and E547, into clinical development,” commented Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals.
  • Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient on the transaction, and Fenwick & West LLP acted as legal counsel for Escient.

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

Retrieved on: 
화요일, 4월 23, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Goldman Sachs, American Academy, Hart–Scott–Rodino Antitrust Improvements Act, B cell, LLP, Safety, Skin, Vital signs, Centerview Partners, Research, ECG, Covington & Burling, MRGPRX2, MRGPRX4, Autoimmunity, Therapy, Science, Escient, Incidence, Patient, Acquisition, Multimedia, Atopic dermatitis, CSU

This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte.

Key Points: 
  • This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
  • “These drug candidates are the result of the highly innovative research performed by Escient’s employees and scientific collaborators,” said Joshua A. Grass, President and Chief Executive Officer, Escient.
  • Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient on the transaction and Fenwick & West LLP acted as legal counsel for Escient.
  • The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is +1 201-612-7415.

Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum

Retrieved on: 
수요일, 12월 7, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Peptide, Therapy, Escient, Hives, CSU, Ligand, Itchy, Cytokine, Cold urticaria, Doctor of Philosophy, Skin, B cell, Patient, Translation (biology), Angioedema, Histamine, Chemokine, Pain, Sleep, MRGPRX4, Cholestatic pruritus, MRGPRX2, Tissue, Drug discovery, Atopic dermatitis, Pharmaceutical industry, Vaccine

Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the companys EP262 development program at the 6th GA2LEN Global Urticaria Forum being held in Berlin, Germany, December 7-8, 2022.

Key Points: 
  • Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the companys EP262 development program at the 6th GA2LEN Global Urticaria Forum being held in Berlin, Germany, December 7-8, 2022.
  • EP262, a potent, highly selective antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), represents a novel, targeted approach to the treatment of mast cell-mediated disorders.
  • In chronic inducible urticaria (CIndU), hives are induced by specific triggers such as cold exposure (cold urticaria) or touch (symptomatic dermographism), among others.
  • Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders.

Escient Pharmaceuticals Announces $120 Million Series C Financing

Retrieved on: 
월요일, 11월 28, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, NEA, Skin, Tissue, Pain, AD, CSU, Gastrointestinal tract, Carma, OUP, Therapy, Cholestatic pruritus, MRGPRX4, Allergy, MRGPRX2, Atopic dermatitis, Pharmaceutical industry, Vaccine, Thakeham

Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the closing of a $120 million Series C financing.

Key Points: 
  • Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the closing of a $120 million Series C financing.
  • Proceeds from the financing will be used to advance the companys pipeline of two first-in-class product candidates in several indications.
  • Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders.
  • Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors.

Escient Pharmaceuticals Initiates Phase 2 PACIFIC Study Evaluating EP547, An Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus

Retrieved on: 
목요일, 11월 17, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Trial of the century, Primary biliary cholangitis, Skin, Primary sclerosing cholangitis, Bilirubin, PBC, PK, Itch, Cholestatic pruritus, Doctor of Philosophy, FRCP, Safety, PSC, MRGPRX4, Division, Therapy, Neuron, University, Hepatology, MRGPRX2, MD, University of Toronto, Patient, Pharmaceutical industry, Tourism, Gastroenterology

The Phase 2 study, PACIFIC, is a randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety and tolerability of EP547 in subjects with cholestatic pruritus due to primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).

Key Points: 
  • The Phase 2 study, PACIFIC, is a randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety and tolerability of EP547 in subjects with cholestatic pruritus due to primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).
  • Intense, unrelenting itch is a common and often debilitating symptom for people living with PBC, PSC and other cholestatic liver diseases.
  • The Phase 2 PACIFIC study will enroll approximately 58 patients with moderate-to-severe pruritus due to PBC or PSC.
  • The companys pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.

Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires

Retrieved on: 
수요일, 11월 16, 2022
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, University of California, San Francisco, Sale, AD, Deutsche Bank, Stanford Graduate School of Business, Merck, Atopic dermatitis, Equity, Economics, Cholestatic pruritus, Biochemistry, CFO, Therapy, Alma College, OSI Pharmaceuticals, Los Alamos National Laboratory, Purdue University, Huron, CMC, MRGPRX4, DePaul University, Chemistry, CSU, San Francisco, Quality control, Ohio State University, Growth, MBA, Corporation, Cholestasis, Drug discovery, UCB, Biomedical engineering, Research, University, MRGPRX2, Business, Thomas Weisel Partners, Business development, Doctor of Pharmacy, BioMarin Pharmaceutical, Operational definition, Sanofi, Pharmaceutical industry, Management, Bayer

Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the addition of three key new members to its leadership team.

Key Points: 
  • Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the addition of three key new members to its leadership team.
  • We are pleased to welcome Aaron, David, and Greg to Escient Pharmaceuticals said CEO Joshua Grass.
  • Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders.
  • Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors.

Escient Pharmaceuticals Appoints Joshua Grass, MBA as CEO

Retrieved on: 
수요일, 1월 5, 2022
Health, Pharmaceutical, Therapy, Drug discovery, Winfield F. Prime, University, Entrepreneurship, Acquisition, BioMarin Pharmaceutical, Growth, California Polytechnic State University, Director, Research, Escient, Business, MRGPRX2, CEO, MBA, Â, Board, Board of directors, MRGPRX4, Biotechnology, Leadership, Pharmaceutical industry, Management, Science, Biology, GPCR

Escient Pharmaceuticals, a clinical-stage company focused on discovering and developing novel, first-in-class therapies to address serious, unserved medical needs, today announced the appointment of Joshua Grass, MBA as Chief Executive Officer effective immediately.

Key Points: 
  • Escient Pharmaceuticals, a clinical-stage company focused on discovering and developing novel, first-in-class therapies to address serious, unserved medical needs, today announced the appointment of Joshua Grass, MBA as Chief Executive Officer effective immediately.
  • I am very excited to be leading Escient during this next phase in its evolution, said Mr. Grass.
  • Prior to joining Escient, Mr. Grass most recently served as CEO of Modis Therapeutics.
  • Escient Pharmaceuticals is a clinical-stage company focused on discovering and developing novel, first-in-class therapies to address serious, unserved medical needs.

Escient Pharmaceuticals Announces Data Presentations Highlighting the Preclinical and Clinical Development of EP547 at AASLD The Liver Meeting® Digital Experience 2021

Retrieved on: 
목요일, 11월 4, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Kidney, Digital, Liver support system, Biology, Cholestatic pruritus, Biotechnology, AASLD, Chronic kidney disease, Other, PBC, Association, Neuron, Institute of Liver and Biliary Sciences, Abstract (summary), Drug development, Escient, Heme, American Association for the Study of Liver Diseases, Patient, Drug discovery, Itch, Bilirubin, Adult, Primary biliary cholangitis, MOA, Tissue, Skin, MRGPRX4, Liver, American Association, The X Factor Digital Experience, MRGPRX2, Pharmaceutical industry, Vaccine, EP547 for Cholestatic and Uremic Pruritus, Escient Pharmaceuticals, EP547 FOR CHOLESTATIC AND UREMIC PRURITUS, ESCIENT PHARMACEUTICALS

Abstracts are now available on the organizations website and the posters will become available beginning at 8 a.m.

Key Points: 
  • Abstracts are now available on the organizations website and the posters will become available beginning at 8 a.m.
  • By blocking these pruritogens from activating MrgprX4, Escient believes EP547 has the potential to effectively treat both cholestatic and uremic pruritus.
  • Pruritus is a common, often severe, and life-altering condition in patients with chronic liver and kidney disease.
  • Drug development to address cholestatic and uremic pruritus has been hampered by the lack of basic biological understanding of the relevant mechanisms.